Evidence map›Paper›PMID 40596671›Full record

ArticleScientific reports2025

Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.

Hanna Saadani, Else A Aalbersberg, Mutamba T Kayembe, John B A G Haanen, Otto S Hoekstra, Ronald Boellaard, Marcel P M Stokkel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Prognostic value of TMTV and Dmax calculated fromEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanna SaadaniDepartment of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, the Netherlands. h.saadani@nki.nl.
Else A AalbersbergDepartment of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, the Netherlands.
Mutamba T KayembeDepartment of Biometrics, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, the Netherlands.
John B A G HaanenDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, the Netherlands.
Otto S HoekstraDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, the Netherlands.
Ronald BoellaardDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, the Netherlands.
Marcel P M StokkelDepartment of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary aim of this study was to assess whether there is an association between pretreatment fluorine-18-labelled fluorodeoxyglucose([

Indexed as

Immune Checkpoint InhibitorsMelanomaPositron-Emission TomographyAdultAgedAged, 80 and overFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPositron Emission Tomography Computed TomographyPrognosisRetrospective StudiesFluorodeoxyglucose F18Immune Checkpoint Inhibitors[18F]FDG PET/CTDisseminationFeaturesImmunotherapyMelanomaSurvival

Identifiers

PMID40596671
PMCPMC12218385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.